AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04694274 — intervention group
Intervention type: PROCEDURE
Intervention: physical therapy
Description: Home-exercise program included exercises for passive and active stretching, joint mobilization, passive extension, and translational movements to the right, left, and forward.
Study NCT04694274 — intervention group
Intervention type: DEVICE
Intervention: placebo splint
Description: The placebo splint was made of thin heat-treatable foil (0.5 mm). The foil was heated and printed over a plaster model of the upper jaw resulting in a very thin film over the occlusal surfaces of all teeth.
Study NCT03437005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desonide 0.05%
Description: Desonide 0.05% ointment topically twice daily for two weeks
Study NCT03437005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2%
Description: Ketoconazole 2% cream topically twice daily for two weeks
Study NCT02244866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pergoveris (FSH and LH)
Description: Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Study NCT02244866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alpha (FSH)
Description: Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Study NCT04020900 — intervention group
Intervention type: OTHER
Intervention: Respiratory management
Description: Data on respiratory management were collected at different time: data regarding the induction period, ventilatory parameters set and measured during a stable period, ventilatory change made during anaesthesia, use of recruitment manoeuvres, data regarding weaning and extubation
Study NCT00325468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 162
Description: AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
Study NCT04357574 — intervention group
Intervention type: OTHER
Intervention: Telehealth
Description: patients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
Study NCT01063400 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
Study NCT04827511 — intervention group
Intervention type: OTHER
Intervention: Refraction measurement with auto-ref-keratometer Canon
Description: Refractive measurement and vitamin D level dosing
Study NCT04478968 — intervention group
Intervention type: OTHER
Intervention: presence of AVF
Description: Functioning AVF may have cardiotoxic potential
Study NCT03033823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
Study NCT03033823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
Study NCT00622128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventing Aggressive Behavior in Demented Patients
Description: Preventing Aggressive Behavior in Demented Patients
Study NCT03662854 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline
Description: Patients will receive 2 mL of Phosphate Buffered Saline separated by 6 weeks (total of 4 mL of Phosphate Buffered Saline)
Study NCT01780584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral T3 Low dose
Description: Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
Study NCT01780584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
Study NCT01780584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
Study NCT01780584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral T3 high dose
Description: Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
Study NCT02330861 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: combowire and IVUS
Study NCT01126177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1a
Description: SNG001, IFN-β1a solution for inhalation
Study NCT01126177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (excipients of the SNG001 solution only)
Study NCT03427879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low flavonoid beverage
Description: A low flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), placebo blueberry powder (2.4%), alkalized cocoa powder (1.6%), and whey protein isolate (0.6%). The beverage will contain approximately 5mg flavonoids per serving.
Study NCT03427879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High flavonoid beverage
Description: A high flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), blueberry powder (2.4%), cocoa powder (1.6%), green tea extract (0.1%) and whey protein isolate (0.6%). The beverage will contain approximately 620 mg flavonoids per serving.
Study NCT00496041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Registry
Description: A Registry will be used.
Study NCT03732209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
Study NCT00562484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Limited Influenza Vaccine
Description: A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
Study NCT00562484 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study NCT02375607 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Algometer
Description: Algometer performed patients
Study NCT01114334 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-Based Medical Management
Description: We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
Study NCT01114334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline-Based Medical Management
Description: We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
Study NCT01114334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing for Depression
Description: Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
Study NCT03221816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenavit®
Description: The experimental group received one tablet of Tenavit® daily for a period of 4 months.
Study NCT03221816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
Study NCT01214967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Education
Description: psycho-educational intervention
Study NCT02464163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panblok
Description: Intramuscular injection
Study NCT02464163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHA adjuvant
Description: Intramuscular injection
Study NCT02741661 — intervention group
Intervention type: OTHER
Intervention: No intervention. Observational study
Description: No intervention
Study NCT01695174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xifaxan
Study NCT01149564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iv ibuprofen
Study NCT01149564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ibuprofen
Study NCT04576520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacopuncture therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
Study NCT04576520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
Study NCT00591565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: acamprosate 333mg tab, 3 by mouth 3 times a day
Study NCT04895657 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Piperacillin/Tazobactam Continuous infusion
Description: Continuous infusion
Study NCT04895657 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Piperacillin/Tazobactam Intermittent infusion
Description: Intermittent infusion
Study NCT04339153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training for Disruptive Behaviours
Description: Critically, PT also involves education about autism during the initial sessions, and thus benefits of PT are inferred to come from the specific training.
Study NCT04835610 — intervention group
Intervention type: DEVICE
Intervention: pvi
Description: The Plethysmographic Variability Index (PVI) can be measured with both finger and forehead probes. Vasoconstriction may reduce the reliability of PVI measurements in pediatric surgical patients prone to hypothermia. The vascular structure of the forehead area is resistant to changes in vasomotor tonus. The aim of our study is to compare the efficacy of PVI values measured at the finger and forehead areas to predict fluid responsiveness in these patients.
Study NCT03056638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix monthly for 6 months
Study NCT03056638 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiosurgery (SBRT)
Description: SBRT 8 Gy x 5
Study NCT02323542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition intervention with cereal products
Description: acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
Study NCT02323542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition intervention with cereal products
Description: acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
Study NCT02075931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity feedback with group meetings
Description: Physical activity feedback
Study NCT02075931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention
Study NCT03732209 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Thinking
Description: Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
Study NCT03206346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin
Description: Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
Study NCT03206346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo, capsules daily for 5 days.
Study NCT02362490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alpha 2a
Description: in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
Study NCT03541759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone Hcl 4Mg Tab
Description: Hydal retard 4Mg Tab 2 times after surgery as basic medication. Hydal retard 2.6Mg maximum 2 per 24h when NRS > 5.
Study NCT03541759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramide 15mg s.c.
Description: Dipidolor 15mg s.c. 2 times after surgery as basic medication. Dipidolor 7.5mg s.c. maximum 2 per 24h when NRS > 5.
Study NCT04551378 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04551378 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT02034747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study NCT02034747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: oral
Study NCT01149980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram Hydrobromide
Description: Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
Study NCT01149980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram Hydrobromide
Description: Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
Study NCT02034747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: oral
Study NCT02034747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: oral
Study NCT03775850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EDP1503
Description: 4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU)
Study NCT03775850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg given by intravenous (IV) infusion once every 3 weeks
Study NCT06229561 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Feasibility of soft tissue graft after immediate implant placement
Study NCT03282448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family therapy
Description: The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus \& Miller, 2014).
Study NCT03045289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-Based Diet
Description: Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
Study NCT04769089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with Pulse Dye Laser
Description: Pulse Dye laser treatment will be applied to one randomized area with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s.
Study NCT04769089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with CO2 Laser
Description: CO2 laser treatment will be applied to one randomized area with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
Study NCT04769089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with combination of pulse dye laser and CO2 laser.
Description: Pulse Dye laser and CO2 treatment will be applied to one randomized area. Pulse Dye will be applied with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s followed by the CO2 laser treatment with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
Study NCT04769089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: One area will be randomized to receive no laser treatment.
Study NCT00839683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Tablets, Oral, 20 mg, Single Dose
Study NCT00839683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, Single Dose
Study NCT04248049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
Study NCT04248049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
Study NCT03740932 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Study group (group A)
Description: Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure
Study NCT00839683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Oral, 40 mg, Single Dose
Study NCT00839683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Tablets, Oral, 320 mg, Single Dose
Study NCT03964857 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Refined olive oil (ROO)
Description: Consumption of chicken dishes made with ROO for a period of 8 weeks
Study NCT03964857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended Oil 1 (BO1)
Description: Consumption of chicken dishes made with BO1 for a period of 8 weeks
Study NCT03964857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended Oil 2 (BO2)
Description: Consumption of chicken dishes made with BO2 for a period of 8 weeks
Study NCT02630173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing was done in both the groups
Study NCT02630173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing was done in both the groups
Study NCT02630173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endodontic treatment
Description: In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
Study NCT03686943 — intervention group
Intervention type: OTHER
Intervention: Family pharmacy
Description: Observation of the family pharmacy in elderly group
Study NCT03628664 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT scan
Description: Assessment of the actual posterior condylar angle using the CT scan
Study NCT00478777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.
Study NCT00478777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
Study NCT02677571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral Thoracic block
Study NCT02677571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectorals nerve block
Study NCT02677571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25%
Study NCT02677571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study NCT04547101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104，6 mg/kg IV，every 2 weeks (Q2W)
Study NCT04711018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laryngoscopy
Description: The laryngoscopy is performed with the help of an appropriate size Macintosh blade. The patient's head is held in the sniffing position. External manipulation is not used for improving the view in this investigation.